“Is cancer immune therapy right for me?” These days, it’s a question many patients ask. Only you and your doctor can answer it. However, research from Cold Spring Harbor Laboratory Assistant Professor Peter Westcott and colleagues at the Massachusetts Institute of Technology may offer some intriguing food for thought.
A recent study suggests that in some cases, subclonal tumor mutations may be harder for the immune system to identify than clonal mutations. Just what does that mean? And more importantly, what might it mean for cancer patients? We break it down using easy-to-follow motion infographics. Press play for a simple explanation and follow the link below to find out more.
Read the related story: In cancer immunotherapy, more isn’t necessarily better